Health Care · Pharmaceutical Preparations

LQDA Liquidia Corp SEC Filings & Insider Trading Activity 2026

company
CIK 1819576153 filings
Russell 2000

LQDA at a glance

Liquidia Corp (LQDA, SEC CIK 1819576) filed its latest 10-K annual report on March 5, 2026, a 10-Q quarterly report on November 10, 2026, an 8-K current report on November 18, 2026 and Form 4 insider filings as recently as November 18, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2025 (FY2025), Liquidia Corp (LQDA) reported revenue of $158.3 million (up 1031.2% from FY2024) and a net loss of $68.9 million. Diluted EPS was -$0.80.
  • As of September 30, 2026, 28 institutional investment managers tracked by SignalX reported holding Liquidia Corp (LQDA) shares worth $982.8 million in 13F-HR filings.
  • The most recent insider open-market sale reported on Form 4 was by Adair Jason on October 26, 2026 of 688 shares at $43.19 per share.
  • In the last 90 days, LQDA insiders reported 0 open-market purchases ($0) and 15 open-market sales ($10.6M) on Form 4, a net sale of $10.6M.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$158.3M
+1031.2% vs prior year
Insiders · 90 days
0 buys · 15 sells
Net −$10.6M
13F holders
28 funds
$982.8M · −2 vs prior quarter
Latest 8-K
Nov 18, 2026
Item 5.02

AI 10-K Annual Report Analysis

Latest 10-K, fiscal year ended Dec 31, 2025

Full analysis →

Business Overview

  • Core business model: Development and commercialization of inhaled treprostinil therapies for PAH and PH-ILD leveraging proprietary PRINT particle engineering technology
  • New product launch: FDA approved and commercialized YUTREPIA inhalation powder in May-June 2025, designed for higher dosing and improved lung delivery
  • Strategic emphasis: Positioning YUTREPIA as first-choice prostacyclin across PAH and PH-ILD, targeting dose titration beyond existing inhaled therapies like Tyvaso
  • Quantitative metric: YUTREPIA studied at doses up to 424 mcg QID, significantly higher than 64 mcg max dose for Tyvaso DPI, enabling extended inhaled therapy use
  • Noteworthy filing fact: YUTREPIA developed via 505(b)(2) pathway faces ongoing patent litigation by United Therapeutics seeking FDA approval withdrawal

Risk Factors

  • Cybersecurity risk with potential material disruption of product development programs and financial losses due to IT system failures or data breaches
  • Board Audit Committee oversight of cybersecurity risks with regular management reporting on security controls and incident response effectiveness
  • Dependence on head of IT with 25+ years cybersecurity experience managing day-to-day information security and threat detection operations
  • Incident response led by CEO, CFO, General Counsel, and supported by external legal and cybersecurity advisors to contain and mitigate breaches
  • Potential reputational risk and unauthorized release of confidential information impacting business and financial condition

Management Discussion & Analysis

  • Revenue $158.3M in 2025 vs $14.0M in 2024; product sales $148.3M from YUTREPIA launches, service revenue down 28% to $10.0M
  • Operating loss improved to $(51.4)M in 2025 vs $(121.3)M in 2024; SG&A rose 93% to $157.2M, R&D decreased 18% to $39.3M
  • Best segment: Product sales $148.3M in 2025; worst segment: Service revenue declined 28% to $10.0M
  • Cash $190.7M end 2025; net cash from financing $59.7M; CapEx $4.3M; license payment $2.0M; no buybacks or dividends disclosed
  • Outlook risks: FDA approval maintenance, YUTREPIA commercialization success, pump availability constraint on Treprostinil Injection, high R&D costs for L606 development

AI summary of the LQDA 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Risk Factors

  • New trade-policy risk: April 2026 executive order sought 100% tariffs on imported branded or patented pharmaceuticals without U.S. manufacturing
  • Regulatory risk: Settlement Agreement removed PH-ILD from YUTREPIA’s label, narrowing its commercial opportunity versus Tyvaso
  • Competitive risk: Generic Tyvaso entered the market effective January 1, 2026
  • Financial risk: HCR facility requires minimum cash and cash equivalents of $45.0 million
  • Compliance risk: August 2026 SEC-FDA information-sharing agreement increased insider-trading enforcement exposure for FDA-related information

Management Discussion & Analysis

  • Quarterly revenue $225.3M, up $171.0M from $54.3M YoY, driven by YUTREPIA product sales
  • Product sales $222.7M vs $51.7M YoY, strongest line; service revenue $2.6M vs $2.7M
  • Operating loss $263.5M vs $1.8M income, including $389.7M litigation settlement charge
  • Cash provided by operations $279.9M vs $79.9M used YoY; investing use $32.0M, financing use $42.5M
  • PH-ILD label removal and promotion cessation, $105.4M cash restricted for UTC payments, further $145.4M payable by April 2027

AI summary of the LQDA 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 18, 2026Full analysis →

Item 5.02: Departure/Appointment of Directors or Principal Officers

  • Russell Schundler appointed Chief Strategy Officer and General Counsel, effective November 16, 2026
  • Annual base compensation increased to $625,000, with target bonus raised to 60% of base salary
Filed Nov 10, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Liquidia announced third-quarter 2026 financial results for the period ended September 30, 2026
  • Corporate update accompanies the results, with substantive details in Exhibit 99.1

Item 8.01: Other Events

  • Updated corporate presentation signals refreshed messaging for healthcare conferences, analysts, and investors
  • Exhibit 99.2 contains the substantive investor-facing information and may affect market expectations

Item EX-99.2: Item EX-99.2

  • Q3 2026 net product sales $222.7M, up 31% sequentially, marking the fifth consecutive quarterly growth period
  • YUTREPIA demand broadened to 1,300 prescribers, with over 60% generating at least two referrals

Item EX-99.1: Item EX-99.1

  • Q3 2026 YUTREPIA sales reached $222.7 million, up 31% sequentially and sharply strengthening the commercial growth profile
  • Global settlement resolved six United Therapeutics lawsuits, preserving YUTREPIA access but requiring $380.7 million in payments during 2026 and 2027
Filed Oct 14, 2026Full analysis →

Item EX-99.1: Item EX-99.1

  • Global settlement ends all six lawsuits with United Therapeutics, removing litigation overhang and securing uninterrupted PAH commercialization
  • $380.7M net payments across 2026 and 2027, including $175M within 30 business days and $145.4M in two installments

Item 1.02: Termination of a Material Definitive Agreement

  • Three legacy agreements terminate only after settlement payments are made, creating execution risk before Liquidia gains full contractual release
  • Promotion Agreement ends for RareGen Litigation proceeds after the Sandoz payment, preserving certain third-quarter 2026 payment obligations

Item 8.01: Other Events

  • Liquidia settled all ongoing litigation with UTC, eliminating a major legal overhang
  • Concurrent Sandoz, Henderson and PBM agreements address antitrust and breach-of-contract claims tied to RareGen Litigation

Item 7.01: Regulation FD Disclosure

  • Cash and equivalents of $396.1 million as of September 30, 2026, supporting near-term operations and development funding
  • Settlement-related payments, Sandoz agreements and Treprostinil Injection rights transfer could materially alter cash flows

Item 1.01: Entry into a Material Definitive Agreement

  • Continued YUTREPIA marketing, but PH-ILD indication and promotion permanently removed, narrowing the product’s addressable market
  • $320.4M total UTC payments, including $175.0M within 30 business days and $145.4M in installments by January 31 and April 30, 2027

AI summaries of LQDA 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for LQDA

Don't miss the next LQDA filing

  • Alerts as it files. A push when LQDA files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut LQDA, by share count.
  • Ask anything. An AI agent that reads every LQDA filing and answers with sources.

LQDA alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
KIRSCH ARTHUR SMNov 16, 2026-
KIRSCH ARTHUR SMNov 16, 2026$20.36
Alterson HaroldANov 16, 2026-
Schundler RussellANov 16, 2026-
Adair JasonSellOct 26, 2026$43.19
Boyle DanaSellOct 26, 2026$43.19
Kaseta MichaelSellOct 12, 2026$28.48
Adair JasonSellOct 12, 2026$28.48

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue$17.5M$14.0M$158.3M
Operating Income--$121.3M-$51.4M
Net Income-$78.5M-$130.4M-$68.9M
Op. Margin--866.6%-32.5%
Net Margin-448.9%-931.7%-43.5%
Balance Sheet
Total Assets-$230.3M$327.9M
Equity-$77.3M$44.7M
ROE--168.7%-154.0%
Per Share
EPS$-1.21$-1.66$-0.80
Cash Flow
Operating CF--$93.4M-$35.7M
CapEx$1.3M$4.9M$4.3M

Source: XBRL data in Liquidia Corp (LQDA)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate LQDA share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
LQDA shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202628$982.8M
Q2 202630$2.35B
Q1 202626$731.7M
Q4 202525$729.2M
Q3 202525$516.4M
Q2 202522$211.6M
Q1 202521$172.7M
Q4 202416$98.3M
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
New Positions
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 193 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

LQDA filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
4Nov 18, 2026--
4Nov 18, 2026--
4Nov 18, 2026--
8-KNov 18, 2026Analysis-
10-QNov 10, 2026Analysis
8-KNov 10, 2026Analysis-
4Oct 28, 2026--
4Oct 28, 2026--
8-KOct 14, 2026Analysis-
4Oct 13, 2026--
4Oct 13, 2026--
4Oct 13, 2026--
4Oct 13, 2026--
4Oct 13, 2026--
4Oct 13, 2026--
4Oct 13, 2026--
4Oct 13, 2026--
4Oct 13, 2026--
4Oct 7, 2026--
8-KSep 30, 2026Analysis-
4Sep 15, 2026--
8-KSep 3, 2026Analysis-
4Sep 3, 2026--
4Aug 25, 2026--
4Aug 21, 2026--

Related Health Care companies

All Health Care →

LQDA SEC filings: frequently asked questions

Are LQDA insiders buying or selling?

In the last 90 days, Liquidia Corp (LQDA) officers, directors and 10% owners reported no open-market purchases and 15 open-market sales worth $10.6 million by 11 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.

Which institutions hold LQDA stock?

As of September 30, 2026, the largest Liquidia Corp (LQDA) holders among the 13F filers tracked by SignalX were BlackRock ($340.8 million), Vanguard Capital Management LLC ($98.0 million), State Street Corp ($97.3 million), Vanguard Portfolio Management LLC ($85.2 million), Bank of America Corp ($55.5 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What was LQDA's revenue in fiscal year 2025?

For the fiscal year ended December 31, 2025 (FY2025), Liquidia Corp (LQDA) reported revenue of $158.3 million (up 1031.2% from FY2024) and a net loss of $68.9 million. Diluted EPS was -$0.80. The figures come from the XBRL data in the 10-K.

What are the main risks in LQDA's latest 10-K?

In the 10-K filed March 5, 2026, Liquidia Corp (LQDA) flagged: Cybersecurity risk with potential material disruption of product development programs and financial losses due to IT system failures or data breaches. Board Audit Committee oversight of cybersecurity risks with regular management reporting on security controls and incident response effectiveness. (AI summary of the Risk Factors section.)

What did LQDA report in its latest 8-K?

Liquidia Corp (LQDA) filed an 8-K on November 18, 2026 reporting Item 5.02 (Departure/Appointment of Directors or Principal Officers). Russell Schundler appointed Chief Strategy Officer and General Counsel, effective November 16, 2026.

What are the latest LQDA SEC filings?

Liquidia Corp (LQDA) filed its latest 10-K annual report on March 5, 2026, a 10-Q quarterly report on November 10, 2026, an 8-K current report on November 18, 2026 and a Form 4 insider filing on November 18, 2026.

What is LQDA's SEC CIK number?

Liquidia Corp (LQDA)'s SEC Central Index Key (CIK) is 1819576. EDGAR lists every LQDA filing under that number.

Ask anything about LQDA

The research agent reads LQDA's filings, financials, insider trades and 13F holders, then answers with sources.